10-Q · May 12, 2026
Nkarta, Inc. reported a first-quarter loss of $27.8 million and a diluted EPS of -$0.37, missing consensus EPS estimates of -$0.30. Although the company is still pre-revenue with no product sales, its cash and…
Earnings analysis · 10-Q
NKTX earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Nkarta remains a clinical-stage company with no disclosed product revenue, and second-quarter diluted EPS of negative $0.54 was worse than both the prior quarter’s negative $0.37 and the prior-year quarter’s negative…
Read full summary
Nkarta remains a clinical-stage company with no disclosed product revenue, and second-quarter diluted EPS of negative $0.54 was worse than both the prior quarter’s negative $0.37 and the prior-year quarter’s negative $0.31. The company retains substantial liquidity of $243.2 million and expects its current plan to be funded into 2029, while R&D spending rose 20% year over year to $54.0 million for the first six months. Protocol amendments for outpatient dosing, re-dosing and an RA cohort expand the NKX019 opportunity but also increase execution, safety, enrollment and manufacturing risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.54
What stood out
-
Quarterly Loss Deepened
Second-quarter diluted EPS was a loss of $0.54, worsening from a $0.37 loss in 2026 Q1 and a $0.31 loss in 2025 Q2.
-
Cash Runway Extends Into 2029
Cash, cash equivalents, restricted cash and investments totaled $243.2 million as of June 30, 2026, with management expecting funding into 2029.
-
R&D Spending Increased 20%
Research and development expense increased to $54.0 million for the six months ended June 30, 2026, from $45.0 million in the comparable 2025 period, a $9.0 million or 20% increase.
-
NKX019 Trial Protocol Expanded
FDA-agreed protocol amendments support outpatient NKX019 administration, potential re-dosing, an RA cohort in Ntrust-2 and removal of geographic monitoring requirements; the amended protocols reduce post-dose monitoring from 24 hours to 2 hours.
-
Organization Supports Clinical Programs
Nkarta had 106 full-time employees as of June 30, 2026, supporting continued clinical development and manufacturing activities.
What to watch
-
Large and Continuing Operating Losses
The amended risk factor states that net losses were $68.2 million for the six months ended June 30, 2026, while accumulated deficit reached $716.5 million; management expects increasing operating losses as NKX019 development continues.
-
Additional Financing May Be Required
The company states that advancing NKX019 or another product candidate into pivotal trials will require additional capital. As of June 30, 2026, cash, cash equivalents, restricted cash and investments were $243.2 million, and future equity financing could dilute existing holders.
-
Clinical Enrollment Remains Challenging
Enrollment remains a material risk across the two Phase 1/2 autoimmune studies, Ntrust-1 and Ntrust-2, which cover six named autoimmune indications: lupus nephritis, pMN, scleroderma, myositis, AAV and RA. The filing states that the company has had significant enrollment challenges and may continue to experience them.
-
Outpatient and Re-Dosing Safety Risk
Moving to outpatient dosing reduces required monitoring from 24 hours to 2 hours, while safety at higher dose levels remains under evaluation. The filing also identifies additional safety risks from re-dosing, including cumulative toxicity and immunogenicity.
-
Manufacturing Asset Impairment Risk
The filing identifies a newly highlighted impairment risk after the company decided during the quarter ended June 30, 2026 to sublease part of its facility and stop using certain equipment, resulting in impairment charges during the quarter.
-
Ownership and Share-Sale Overhang
As of August 5, 2026, directors, executive officers and holders of more than 5% of the company’s stock beneficially owned 37% of common stock, while 8,417,761 shares had registration rights and 74,624,822 shares were outstanding including pre-funded warrants, creating potential governance and selling-pressure risks.
Management's outlook
No numeric revenue or EPS guidance was provided. Management previously stated that cash and cash equivalents of $243.2 million were expected to fund the current operating plan into 2029; explicit quantitative outlook was otherwise deferred to the earnings release/call.
Earlier filings 4
10-K · March 25, 2026
Nkarta is a clinical-stage company focused on an allogeneic CAR NK platform with lead program NKX019 (CD19) being evaluated in multiple Phase 1 trials for autoimmune diseases (Ntrust-1, Ntrust-2 and several ISTs). The…
10-Q · November 10, 2025
Nkarta, Inc. reported no product revenue for Q3 2025, continuing its trend of financial losses with a net loss of $21.7 million compared to $28.3 million in Q3 2024. The company showed a slight improvement in EPS,…
10-Q · August 12, 2025
Nkarta reported no product revenue and a continuing net loss but showed modest operating expense reductions and an EPS improvement. Q2 results include net loss per share of $(0.31) (vs $(0.34) in Q2 2024) and total…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.